Moderna, Merck fall on profit taking after massive gains on cancer vaccine trial results
BUZZ-Moderna, Merck fall on profit taking after massive gains on cancer vaccine trial results Updates
** Shares of drugmakers Moderna MRNA.O and Merck MRK.N fall over 8% to $160.3 and 1.3% to $150.3, respectively, in premarket trading
** Companies said on Wednesday a personalized mRNA cancer vaccine together with Merck's immunotherapy Keytruda reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment
** Moderna shares more than doubled on Wednesday, adding over $44 billion to its market value
** "While we were thrilled to see a positive market reaction for the definitive success of the therapeutic cancer vaccine, intismeran autogene, the reception was overly optimistic and creates expectations that we believe will be difficult to meet," Leerink Partners analysts say
** Up to last day's close, MRNA's stock had risen 491% YTD
(Reporting by Akriti Shah and Mariam Sunny in Bengaluru)
((akriti.shah@thomsonreuters.com ; X, formerly Twitter: @AkritiShahh))
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines